Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.71 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 0.71 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.41 |
| ▸ | FAP | Q12884 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280924 | 1.00 | DPP4 (0.71) | DPP4DPP8DPP9OPRD1DPP7 | |
| SCHEMBL4900305 | 0.88 | DPP4 (0.57) | DPP4DPP8DPP9OPRD1DPP7 | |
| SCHEMBL5734729 | 0.85 | DPP4 (0.69) | DPP4DPP8DPP9OPRD1DPP7 | |
| Hydrochloric Acid SCHEMBL5733139 | 0.84 | DPP4 (0.68) | DPP4DPP8DPP9OPRD1DPP7 | |
| SCHEMBL14280925 | 0.79 | DPP4 (0.46) | DPP4DPP8DPP9OPRD1 | |
| SCHEMBL20787862 | 0.78 | SCN9A (0.47) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5735095 | 0.78 | DPP4 (0.60) | DPP4DPP8DPP9OPRD1 | |
| SCHEMBL20787861 | 0.78 | SCN9A (0.47) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5735089 | 0.78 | DPP4 (0.60) | DPP4DPP8DPP9OPRD1 | |
| Trifluoroacetic Acid SCHEMBL5734371 | 0.77 | DPP4 (0.86) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786423-B1 | A PHARMACEUTICAL COMPOSITION FOR TREATING ATAXIA, MULTIPLE SYSTEM ATROPHY OR BALANCE DISORDERS | SHIONOGI & CO (JP) | 2019-03-13 | — | — | EP | disclosed |
| US-20080027116-A1 | Pharmaceutical Composition for Treating Spinocerebellar Ataxia | SHIONOGI & CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027116-A1 | Pharmaceutical Composition for Treating Spinocerebellar Ataxia | ATXN10, ATXN2, SMN1; SMN2 | DPP4 3629/4885DPP8 3338/4885DPP9 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.